HealthEquity (HQY)
(Delayed Data from NSDQ)
$79.87 USD
-0.40 (-0.50%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $79.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.87 USD
-0.40 (-0.50%)
Updated Apr 17, 2024 04:00 PM ET
After-Market: $79.87 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Walgreens (WBA) to Advance Diabetes Care at FFL Conference
by Zacks Equity Research
Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.
2 Medical Stocks to Consider Buying in June
by Shaun Pruitt
With solid top and bottom-line growth on the horizon for HealthEquity (HQY) and iRadimed (IRMD), they are starting to look like viable investments for 2023 and beyond.
Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
McKesson's (MCK) Latest Launch to Give Access to OTC Products
by Zacks Equity Research
McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Masimo's (MASI) solid product suite raises optimism about the stock.
Walgreens Boots' (WBA) Q3 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) U.S. Healthcare business expands, owing to key contract wins, continued partnership growth and a strong focus on execution.
Walgreens (WBA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strategic executions on the United States and the international front is likely to drive Walgreens' (WBA) Q3 revenues.
Wall Street Analysts Predict a 34.21% Upside in HealthEquity (HQY): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 34.2% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.
How Much Upside is Left in HealthEquity (HQY)? Wall Street Analysts Think 26.59%
by Zacks Equity Research
The consensus price target hints at a 26.6% upside potential for HealthEquity (HQY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why HealthEquity (HQY) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Apollo Medical
by Zacks Equity Research
Medpace, HealthEquity and Apollo Medical are part of the Zacks Industry Outlook article.
3 Medical Services Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and AMEH are set to gain the most. However, staffing shortages may disrupt the trend.
HealthEquity (HQY) Surpasses Q1 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the first quarter of fiscal 2024.
HealthEquity (HQY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended April 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 21.95% and 1.91%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 11.11% and 25.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -50% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 50% and 0.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will HealthEquity (HQY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.